• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

年龄及诊断后时间对骨髓增殖性肿瘤患者血栓形成风险的影响:一项基于全国登记的匹配队列研究。

Impact of age and time since diagnosis on thrombosis risk in myeloproliferative neoplasm patients: A nationwide register-based matched cohort study.

作者信息

Batyrbekova Nurgul, Hultcrantz Malin, Ravn Landtblom Anna, Szulkin Robert, Dickman Paul W, Andersson Therese M-L, Syriopoulou Elisavet

机构信息

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.

出版信息

Br J Haematol. 2025 Jul;207(1):189-200. doi: 10.1111/bjh.20141. Epub 2025 Jun 2.

DOI:10.1111/bjh.20141
PMID:40457566
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12234273/
Abstract

Thromboembolism is one of the major complications in myeloproliferative neoplasms (MPNs), especially in the initial years post-diagnosis and with increasing age. This nationwide matched cohort study used Swedish registers to assess whether attained age or time since diagnosis is more important for thrombosis risk. We identified 17 830 MPN patients diagnosed between 2001 and 2021, each matched with 10 population controls by sex, age and diagnosis year. Rates of first thrombosis post diagnosis and hazard ratios (HRs) were estimated using flexible parametric survival models over time since diagnosis and attained age. Thrombosis rates were significantly higher in MPN patients at all ages, especially in the first 2 years post-diagnosis, after which the rates remained higher than in age-matched controls. At 5 years, HR (95% confidence interval) for any thrombosis comparing patients to controls was 1.8 (1.7-1.9) at age 65, 1.6 (1.5-1.7) at age 70 and 1.5 (1.4-1.6) at age 75 and older. Attained age was more important than time since diagnosis, particularly in patients without prior thrombosis. Thrombosis rates were highest within the first 2 years post-diagnosis, then depended more on attained age than on time since diagnosis. These findings emphasize the importance of age and early management in MPN patients to optimize clinical care.

摘要

血栓栓塞是骨髓增殖性肿瘤(MPN)的主要并发症之一,尤其是在诊断后的最初几年以及随着年龄增长时。这项全国性匹配队列研究利用瑞典的登记数据来评估达到的年龄或自诊断以来的时间对血栓形成风险而言哪个更重要。我们确定了2001年至2021年期间诊断的17830例MPN患者,每例患者按性别、年龄和诊断年份与10名人群对照进行匹配。使用灵活的参数生存模型根据自诊断以来的时间和达到的年龄估计诊断后首次血栓形成的发生率和风险比(HR)。各年龄段的MPN患者血栓形成率均显著更高,尤其是在诊断后的前2年,此后该发生率仍高于年龄匹配的对照。在5年时,65岁患者与对照相比发生任何血栓形成的HR(95%置信区间)为1.8(1.7 - 1.9),70岁时为1.6(1.5 - 1.7),75岁及以上时为1.5(1.4 - 1.6)。达到的年龄比自诊断以来的时间更重要,尤其是在既往无血栓形成的患者中。血栓形成率在诊断后的前2年内最高,然后更多地取决于达到的年龄而非自诊断以来的时间。这些发现强调了年龄和早期管理在MPN患者优化临床护理中的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d060/12234273/14c7e523fc96/BJH-207-189-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d060/12234273/d974ac1e9170/BJH-207-189-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d060/12234273/3a507ef2187b/BJH-207-189-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d060/12234273/cf7622a5b370/BJH-207-189-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d060/12234273/14c7e523fc96/BJH-207-189-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d060/12234273/d974ac1e9170/BJH-207-189-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d060/12234273/3a507ef2187b/BJH-207-189-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d060/12234273/cf7622a5b370/BJH-207-189-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d060/12234273/14c7e523fc96/BJH-207-189-g001.jpg

相似文献

1
Impact of age and time since diagnosis on thrombosis risk in myeloproliferative neoplasm patients: A nationwide register-based matched cohort study.年龄及诊断后时间对骨髓增殖性肿瘤患者血栓形成风险的影响:一项基于全国登记的匹配队列研究。
Br J Haematol. 2025 Jul;207(1):189-200. doi: 10.1111/bjh.20141. Epub 2025 Jun 2.
2
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
3
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.未治疗的霍奇金淋巴瘤患者化疗和放疗在第二原发性恶性肿瘤、总生存期和无进展生存期方面的优化:个体参与者数据分析
Cochrane Database Syst Rev. 2017 Sep 13;9(9):CD008814. doi: 10.1002/14651858.CD008814.pub2.
4
Prognosis of adults and children following a first unprovoked seizure.首次无诱因发作后成人和儿童的预后。
Cochrane Database Syst Rev. 2023 Jan 23;1(1):CD013847. doi: 10.1002/14651858.CD013847.pub2.
5
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
6
Long-term hormone therapy for perimenopausal and postmenopausal women.围绝经期和绝经后女性的长期激素治疗
Cochrane Database Syst Rev. 2017 Jan 17;1(1):CD004143. doi: 10.1002/14651858.CD004143.pub5.
7
Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.社区居住的老年人跌倒预防干预措施:系统评价和荟萃分析的益处、危害以及患者的价值观和偏好。
Syst Rev. 2024 Nov 26;13(1):289. doi: 10.1186/s13643-024-02681-3.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
9
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
10
Nutritional interventions for survivors of childhood cancer.儿童癌症幸存者的营养干预措施。
Cochrane Database Syst Rev. 2016 Aug 22;2016(8):CD009678. doi: 10.1002/14651858.CD009678.pub2.

本文引用的文献

1
Thromboembolic events, major bleeding and mortality in essential thrombocythaemia and polycythaemia vera-A matched nationwide population-based study.原发性血小板增多症和真性红细胞增多症中的血栓栓塞事件、大出血和死亡率:一项匹配的全国基于人群的研究。
Br J Haematol. 2024 May;204(5):1740-1751. doi: 10.1111/bjh.19337. Epub 2024 Feb 13.
2
Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.原发性血小板增多症:2024 年诊断、风险分层和治疗更新。
Am J Hematol. 2024 Apr;99(4):697-718. doi: 10.1002/ajh.27216. Epub 2024 Jan 25.
3
Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.
真性红细胞增多症:2024 年诊断、风险分层和治疗更新。
Am J Hematol. 2023 Sep;98(9):1465-1487. doi: 10.1002/ajh.27002. Epub 2023 Jun 26.
4
Modelling multiple time-scales with flexible parametric survival models.使用灵活参数生存模型对多个时间尺度进行建模。
BMC Med Res Methodol. 2022 Nov 9;22(1):290. doi: 10.1186/s12874-022-01773-9.
5
Survival and risk of vascular complications in myelofibrosis-A population-based study from the Swedish MPN group.骨髓纤维化患者的生存和血管并发症风险:来自瑞典 MPN 小组的一项基于人群的研究。
Eur J Haematol. 2022 Oct;109(4):336-342. doi: 10.1111/ejh.13813. Epub 2022 Jun 24.
6
Thromboinflammation in Myeloproliferative Neoplasms (MPN)-A Puzzle Still to Be Solved.骨髓增殖性肿瘤(MPN)中的血栓炎症——一个待解决的难题。
Int J Mol Sci. 2022 Mar 16;23(6):3206. doi: 10.3390/ijms23063206.
7
Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment.骨髓增殖性肿瘤在细胞减灭和抗血栓药物治疗期间的血栓形成
Res Pract Thromb Haemost. 2022 Feb 7;6(1):e12657. doi: 10.1002/rth2.12657. eCollection 2022 Jan.
8
Thrombotic, Vascular, and Bleeding Complications of the Myeloproliferative Neoplasms.骨髓增殖性肿瘤的血栓、血管和出血并发症。
Hematol Oncol Clin North Am. 2021 Apr;35(2):305-324. doi: 10.1016/j.hoc.2020.11.006. Epub 2021 Jan 5.
9
Clinical insights into the origins of thrombosis in myeloproliferative neoplasms.临床视角下骨髓增殖性肿瘤中血栓形成的起源。
Blood. 2021 Mar 4;137(9):1145-1153. doi: 10.1182/blood.2020008043.
10
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.真性红细胞增多症和原发性血小板增多症:2021 年诊断、风险分层和治疗更新。
Am J Hematol. 2020 Dec;95(12):1599-1613. doi: 10.1002/ajh.26008. Epub 2020 Oct 23.